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CASE REPORT
Posterior reversible encephalopathy syndrome (PRES) after bevacizumab
therapy for metastatic colorectal cancer
Mohsin Hamid a, Ali Ghania, Ida Micaily a, Usman Sarwara, Bilal Lashari a and Faizan Malikb
aDepartment of Internal Medicine, Abington Hospital - Jefferson Health, Abington, PA, USA; bDivision of Hematology/Oncology,
University of Maryland Medical Center, Baltimore, MD, USA
ABSTRACT
Posterior reversible encephalopathy syndrome (PRES) is an increasingly recognizable neuro-
clinical syndrome. Clinical and neurological manifestations of PRES include hypertension,
headache, encephalopathy, seizures, and symmetrical white matter changes on brain MRI.
Most common precipitants of PRES are acute medical illness, hypertensive crisis, eclampsia,
immunosuppressive therapy, and chemotherapy. Bevacizumab is a monoclonal antibody that
halts angiogenesis by inhibiting vascular endothelial growth factor. It has gained widespread
popularity in oncology world especially for metastatic and recurrent cancers due to its
inherent ability to stop angiogenesis; a vital step for tumor growth. Bevacizumab has also
been implicated as the cause of PRES due to dysregulation of the blood-brain barrier. We are
reporting a case of PRES induced by Bevacizumab in a patient of colorectal cancer.
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1. Introduction
Hinchey et al. first described posterior reversible
encephalopathy syndrome (PRES) or reversible
posterior leukoencephalopathy syndrome (RPLS)
in 1996 [1]. PRES has been an increasingly recog-
nizable neuro-clinical syndrome due to widespread
and early use of neuroimaging in modern medicine.
Pathophysiology of PRES is related to cytotoxic-
mediated endothelial dysfunction and failure of
blood-brain barrier or resulting hypertension-
induced autoregulatory failure, although other
mechanisms have also been proposed. The presence
of both neurological findings and clinical manifes-
tations are required for diagnosis. A majority of
patients with PRES are hypertensive at presenta-
tion; most common symptoms are headaches,
visual disturbance, and seizures; whereas, the most
common radiological finding is the presence of
symmetrical white matter edema in the parietal-
occipital area [2]. PRES has been increasingly
reported as a side effect of anti-vascular endothelial
growth factor (VEGF) agents and tyrosine kinase
inhibitors, due to increased accessibility and fre-
quent use of medications in these classes of drugs.
Patients presenting with possible PRES should
prompt the physicians to identify and discontinue
any such medications that might have precipitated
it. We are hereby reporting a case of bevacizumab-
induced PRES, and a brief review of literature of its
side-effect profile.
2. Case presentation
48-year-old woman with recently diagnosed stage IV
sigmoid adenocarcinoma with liver metastasis was
started on FOLFOX (folinic acid, 5-fluorouracil, and
oxaliplatin) therapy. She had no known history of hyper-
tension or migraines. Bevacizumab was held initially due
to concerns of rectal bleeding; however, it was added
back into her third cycle of chemotherapy. She
responded well to her treatment, and a repeat CT abdo-
men/pelvis after 3 months of starting chemotherapy
showed interval decrease in the size of the tumor. After
the addition of bevacizumab in the third cycle of
FOLFOX, she started having high blood pressure (BP)
readings with a range of 160–180 mmHg systolic BP.
About a week after the sixth cycle of FOLFOX, which
included the fourth dose of bevacizumab, she started
complaining of a headache. Her headache was mainly
frontal in location, throbbing in nature, continuous and
radiating behind her eyes. She explained this headache as
the worst headaches of her life, prompting a visit to the
emergency department (ED). A non-contrast CT scan of
her head was performed and found to be unremarkable.
She was managed with supportive care with acetamino-
phen andmetoclopramide with partial relief of headache,
and discharged home. Two days later, while driving, she
had a tonic-clonic seizure and was brought to the ED.
On examination, vital signs included BP ranging from
170s to 190s systolic and 80s to 95s diastolic, tempera-
ture: 100 F, pulse: 110/min, oxygen saturation: 99% on
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ambient air, and respiratory rate of 18/min. Physical
examination in the ED was pertinent for confusion and
agitation, rest of the physical examination was unre-
markable. An initial laboratory workup including com-
plete blood count, blood chemistry, coagulation studies,
urinalysis, toxicology screen, lumbar puncture was nega-
tive. Radiographic imaging including non-contrast CT
head was also negative. She was started on an antiepilep-
tic regimen, levetiracetam for seizure prophylaxis.
Electroencephalography (EEG) was unremarkable.
Brain MRI (Figure 1) showed hyperintense T2 signal
intensity in both occipital lobes involving the gray-
white matter consistent with PRES syndrome.
She was initially observed in the neuro-critical care
unit. Intravenous hydralazine was given for persis-
tently elevated BP, which was later switched to oral
amlodipine once she started taking oral diet resulting
in good BP control. Her symptoms resolved by the
third day of hospitalization and she was discharged
on amlodipine for hypertension and levetiracetam as
seizure prophylaxis. A repeat MRI one week after
presentation showed resolving gray-white matter
changes (Figure 2). Later on, FOLFOX was continued
while bevacizumab was held. She did well on che-
motherapy with good control of her BP and didn’t
report any recurrent headaches. Repeat MRI after one
month of the initial presentation showed complete
resolution and seizure prophylaxis was discontinued.
3. Discussion
VEGF plays a major role as an anti-angiogenic factor
that prevents malignant cells from surviving, dividing,
and ultimately metastasizing. VEGF inhibitors were
developed to halt angiogenesis and stop the exponen-
tial growth of malignant cells. Bevacizumab is a huma-
nized monoclonal antibody that impairs the
interaction of VEGF and VEGF receptor by binding
to VEGF-A (a subtype of VEGF) [3]. It was first
approved by the Federal Drug Agency (FDA) in 2004
for metastatic colorectal cancer. It was later approved
for lung, breast, and ovarian cancer, among others,
which has led to its increased use in oncologic practice
[4].
Although well tolerated, the most common adverse
effects reported are hypertension, proteinuria, arterial
thrombosis, delayed wound healing, bleeding, and gas-
trointestinal perforation. Hypertension is the most
common side effect, and the proposed mechanism is a
decrease in the release of nitric oxide from endothelial
cells as a result of VEGF inhibition [5]. The incidence of
hypertension varies from 16–38% [6]; however, the
incidence of grade 3 or 4 hypertension is 16–18% and
is dose-dependent [7]. The single most important risk
factor for the development of hypertension is the age
with one study finding the incidence of hypertension in
patients aged 75 years or older to be 29% as compared
to 10–11% in patients aged 65–74 [8]. Hypertension
usually occurs within the first year of starting therapy
but can occur later as well. Patients should be carefully
followed for new onset or worsening hypertension,
National Cancer Institute recommends checking BP
every week during the first cycle and then every
2–3 weeks for the rest of the treatment. Continue to
Figure 1. Brain MRI showing abnormal signal intensity in the
gray-white matter in both occipital lobes and parietal lobes
posteriorly and in the left frontal lobe.
Figure 2. Brain MRI showing resolving signal changes of frontal
and parietal-occipital regions representing resolving PRES.
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monitor BP 3–6 months after discontinuation of ther-
apy [9]. BP goals and choice of antihypertensive therapy
should be dictated by guidelines of Joint National
Committee on hypertension [10]. Grade I hypertension
defined as asymptomatic or transient (<24 h) increase
of BP to >150/100 mmHg can be managed with careful
monitoring, grade II and III recurrent or persistent
(>24 h) of BP to above 150/100 mmHg necessitate
initiation and addition of antihypertensive therapy; for
grade IV hypertension (hypertensive crises, e.g. PRES),
bevacizumab should be discontinued.
Proteinuria is the secondmost common side effect of
bevacizumab with an incidence ranging from 23–38%.
However, the incidence of grade III/IV proteinuria is
very low, 3% or less and progression to the florid
nephrotic syndrome is rare. Although no direct associa-
tion has been found between the development of pro-
teinuria and PRES, a review done by Tlemsani et al. [11]
suggested that patients who develop new-onset protei-
nuria while on treatment with bevacizumab are at high
risk of PRES. Patients should be screened for protei-
nuria with a urine dipstick every month and if 2
+(100 mg/dL), it should be confirmed by 24-h urine
collection or urine protein to creatinine (UPC) ratio for
further evaluation. Bevacizumab can be continued if
UPC <2 mg/g or 24-h urine protein is ≤2 g.
Bevacizumab should be suspended if UPC> 2 mg/g
and restarted only if proteinuria has resolved, failure
to resolve within 3 months should result in permanent
discontinuation. Development of nephrotic syndrome
is another reason for permanent discontinuation [12].
No therapy has been shown to improve or at least
prevent the worsening of proteinuria, the role of ACE
inhibitors has been controversial in this regard, with
some studies suggesting it might worsen it [13].
Two years after its formal approval, bevacizumab
was noticed to be related to PRES for the first time
[14]. The mechanism by which bevacizumab causes
PRES is not fully understood, although it is
hypothesized that it disrupts the blood-brain barrier
through endothelial dysregulation resulting in
hyperperfusion and vasogenic edema leading to fail-
ure of autoregulation. Bevacizumab-induced hyper-
tension might also play some role, although cases of
bevacizumab-induced PRES have been reported in
normotensive patients [15,16]. The incidence of
PRES with bevacizumab is <0.5% according to the
package insert. Typically, PRES occurs within the
half-life of bevacizumab which is 20 days, as in our
patient symptoms started about 12 days after the
last dose, but it can occur from 16 h to 1 year.
Seizures are the most common presenting com-
plaint, and tonic-clonic in nature. Encephalopathy
is an integral part of presentation present in about
50–80% of patients [17]. Headache is present in
about 50% of patients and mostly gradual in onset
and dull in character. Visual changes, focal
neurological signs, and status epilepticus can be
present [1]. Diagnosis is challenging and can be
wrongly attributed to stroke, infection, or metasta-
sis. A high index of suspicion should be maintained
in someone with new-onset seizures, encephalopa-
thy in the background of elevated BP and ongoing/
previous chemotherapy with drugs known to cause
PRES, such as bevacizumab. Lumbar puncture is
done routinely to rule out infection, but has no
role in identifying PRES. MRI remains the diagnos-
tic modality of choice and helps to rule out other
differentials as described earlier. Removal of the
inciting agent and BP control is the most critical
thing in the management.
No specific drug is recommended for the con-
trol of BP in the acute phase, and continuous
intravenous infusion of any antihypertensive that
is easily titrated might be needed [18]. Severe
fluctuation in BP should be avoided, and the goal
is to reduce the SBP not more than 25% or dia-
stolic BP to 100–105 mmHg in the first 2–6 hours
as there is a risk of ischemia with a more aggres-
sive decrease in BP. Seizures can be controlled
with benzodiazepines. However, any antiepileptic
can be used for the acute management of seizures
with no role of antiepileptic drugs long term.
Antiepileptics should be tapered quickly in
patients without a seizure recurrence and after
resolution of MRI abnormalities. Seizures asso-
ciated with PRES have a good prognosis without
any long-term sequelae [17].
The overall prognosis of PRES after bevacizumab
is favorable, and there have been calls to change its
name to BRES (benign reversible encephalopathy
syndrome) [19]. Successful re-challenge of bevacizu-
mab has also been reported but should be done under
close supervision, and appropriate BP control should
be ensured [20]. The median time to recovery of the
neurological symptoms is 7.5 days [21].
In conclusion, bevacizumab use in on the rise in
the oncology practice, and potentially severe compli-
cations should be considered when implementing this
agent. Physicians should be reminded of its poten-
tially devastating side effect of PRES and the need to
maintain a high index of suspicion in patients pre-
senting with neurological symptoms who have been
or are currently treated with Bevacizumab.
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